On October 20, 2004, Charles River Laboratories International, Inc. and Inveresk Research Group, Inc. completed their merger, thus creating Charles River Laboratories, a leading global partner in providing essential preclinical and clinical drug development services and products to the pharmaceutical and biotechnology industry. The resulting company, with more than 8,000 employees and 100 locations in 20 countries, will be headquartered in Wilmington, Massachusetts and will continue to trade on the New York Stock Exchange. Based on Charles River’s closing price on June 30, 2004, the transaction was valued at approximately US$1.5 billion. CTBR Bio-Research Inc., based in Senneville, Quebec, is among the group of companies forming Charles River Laboratories.
Charles River was represented by Davis Polk & Wardwell in the US with a team comprised of Paul Kingsley, George Bason Jr., Michael Mollerus, Barbara Nims, Tiziana Bason, Steven Williams, Ron Deutsch, Mary Simone and Nora Muller.
Inveresk was represented in the US by Clifford Chance LLP with a team that included John Healy, Viqar Shariff, Jesse Eisenberg, Pia Thadhani, Victor Levy, Hart Holden, Michael Naughton, Jeff Lieberman and Philip Wagman; in Canada by Stikeman Elliott LLP with a team comprised of John Leopold, William Rosenberg and Caroline Boutin; and in the UK by Dickson Minto WS with a team that included Alasdair Proudfoot, Anthony Byrne and Paul Buchan.